Multicystic dysplastic kidney

Summary

Multicystic dysplastic kidney (MONDO:0015988) is a disease with 9 cohort genes and 3 clinical trials.

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Cohort genes: 9
• ClinVar variants: 10
• Phenotypes (HPO): 15
• Clinical trials: 3

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Prevalence at birth	1-5 / 10 000	23.26	Worldwide	Validated

Signs & symptoms

Clinical features (HPO)

15 HPO clinical features (Orphanet curated; top 15 by frequency):

HPO ID	Term	Frequency
HP:0000003	Multicystic kidney dysplasia	Very frequent (80-99%)
HP:0002643	Neonatal respiratory distress	Very frequent (80-99%)
HP:0001622	Premature birth	Frequent (30-79%)
HP:0003270	Abdominal distention	Frequent (30-79%)
HP:0031500	Abdominal mass	Frequent (30-79%)
HP:0000028	Cryptorchidism	Occasional (5-29%)
HP:0000076	Vesicoureteral reflux	Occasional (5-29%)
HP:0000105	Enlarged kidney	Occasional (5-29%)
HP:0000122	Unilateral renal agenesis	Occasional (5-29%)
HP:0001562	Oligohydramnios	Occasional (5-29%)
HP:0000070	Ureterocele	Very rare (<1-4%)
HP:0000074	Ureteropelvic junction obstruction	Very rare (<1-4%)
HP:0000085	Horseshoe kidney	Very rare (<1-4%)
HP:0000822	Hypertension	Very rare (<1-4%)
HP:0030735	Ureterovesical junction obstruction	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	multicystic dysplastic kidney
Mondo ID	MONDO:0015988
MeSH	D021782
Orphanet	1851
ICD-11	1178642763
NCIT	C123031
SNOMED CT	204962002
UMLS	C3714581
MedGen	811388
GARD	0018748
Is cancer (heuristic)	no

Also known as: MCDK · multicystic renal dysplasia

Data availability: 10 ClinVar variants.

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › cystic kidney disease › multicystic dysplastic kidney

Related subtypes (3): non-congenital cyst of kidney, medullary sponge kidney, familial cystic renal disease

Subtypes (2): unilateral multicystic dysplastic kidney, bilateral multicystic dysplastic kidney

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

10 retrieved; paginated sample, class counts are floors:

3 uncertain significance, 2 pathogenic, 2 conflicting classifications of pathogenicity, 2 likely pathogenic, 1 pathogenic/likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
523524	NM_170784.3(MKKS):c.958_959del (p.Leu320fs)	MKKS	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
523354	NM_000297.4(PKD2):c.2284_2287del (p.Tyr762fs)	PKD2	Pathogenic	criteria provided, single submitter
1804040	NM_020706.2(SCAF4):c.1295_1296del (p.Arg432fs)	SCAF4	Pathogenic	criteria provided, single submitter
632606	NM_017412.4(FZD3):c.1616dup (p.Asp539fs)	FZD3	Likely pathogenic	no assertion criteria provided
632604	NM_012310.5(KIF4A):c.794G>T (p.Arg265Leu)	KIF4A	Likely pathogenic	no assertion criteria provided
977155	NM_001429.4(EP300):c.1781C>T (p.Thr594Met)	EP300	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
523387	NM_001009944.3(PKD1):c.5896GTG[1] (p.Val1967del)	PKD1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
267928	46;Y;inv(X)(p11.2q28)mat		Uncertain significance	criteria provided, single submitter
523520	NM_017777.4(MKS1):c.1274-3C>T	MKS1	Uncertain significance	criteria provided, single submitter
374206	NM_001009944.3(PKD1):c.3785A>G (p.His1262Arg)	PKD1	Uncertain significance	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 13 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
SCAF4	Orphanet:528084	Non-specific syndromic intellectual disability
EP300	Orphanet:353284	Rubinstein-Taybi syndrome due to EP300 haploinsufficiency
MKKS	Orphanet:110	Bardet-Biedl syndrome
MKKS	Orphanet:2473	McKusick-Kaufman syndrome
MKS1	Orphanet:110	Bardet-Biedl syndrome
MKS1	Orphanet:220493	Joubert syndrome with ocular defect
MKS1	Orphanet:475	Isolated Joubert syndrome
MKS1	Orphanet:564	Meckel syndrome
PKD1	Orphanet:730	Autosomal dominant polycystic kidney disease
PKD1	Orphanet:88924	Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis
PKD2	Orphanet:730	Autosomal dominant polycystic kidney disease
PRKD1	Orphanet:276145	Malignant epithelial tumor of salivary glands
PRKD1	Orphanet:708019	Congenital heart defect-ectodermal dysplasia- brachydactyly-telangiectasia syndrome

Cohort genes → proteins

9 cohort genes, 9 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	9

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
KIF4A	HGNC:13339	ENSG00000090889	O95239	Chromosome-associated kinesin KIF4A	clinvar
SCAF4	HGNC:19304	ENSG00000156304	O95104	SR-related and CTD-associated factor 4	clinvar
EP300	HGNC:3373	ENSG00000100393	Q09472	Histone acetyltransferase p300	clinvar
FZD3	HGNC:4041	ENSG00000104290	Q9NPG1	Frizzled-3	clinvar
MKKS	HGNC:7108	ENSG00000125863	Q9NPJ1	Molecular chaperone MKKS	clinvar
MKS1	HGNC:7121	ENSG00000011143	Q9NXB0	Tectonic-like complex member MKS1	clinvar
PKD1	HGNC:9008	ENSG00000008710	P98161	Polycystin-1	clinvar
PKD2	HGNC:9009	ENSG00000118762	Q13563	Polycystin-2	clinvar
PRKD1	HGNC:9407	ENSG00000184304	Q15139	Serine/threonine-protein kinase D1	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
KIF4A	Chromosome-associated kinesin KIF4A	Iron-sulfur (Fe-S) cluster binding motor protein that has a role in chromosome segregation during mitosis.
SCAF4	SR-related and CTD-associated factor 4	Anti-terminator protein required to prevent early mRNA termination during transcription.
EP300	Histone acetyltransferase p300	Functions as a histone acetyltransferase and regulates transcription via chromatin remodeling.
FZD3	Frizzled-3	Receptor for Wnt proteins.
MKKS	Molecular chaperone MKKS	Probable molecular chaperone that assists the folding of proteins upon ATP hydrolysis.
MKS1	Tectonic-like complex member MKS1	Component of the tectonic-like complex, a complex localized at the transition zone of primary cilia and acting as a barrier that prevents diffusion of transmembrane proteins between the cilia and plasma membranes.
PKD1	Polycystin-1	Component of a heteromeric calcium-permeable ion channel formed by PKD1 and PKD2 that is activated by interaction between PKD1 and a Wnt family member, such as WNT3A and WNT9B.
PKD2	Polycystin-2	Forms a nonselective cation channel.
PRKD1	Serine/threonine-protein kinase D1	Serine/threonine-protein kinase that converts transient diacylglycerol (DAG) signals into prolonged physiological effects downstream of PKC, and is involved in the regulation of MAPK8/JNK1 and Ras signaling, Golgi membrane integrity and tr…

Protein-family classification

Druggable: 3 · Difficult: 1 · Unknown: 5 · Druggable fraction: 0.33

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Antibody/Immunoglobulin	1	3.2×	0.532
Kinase	1	3.1×	0.532
GPCR	1	2.7×	0.532
Other/Unknown	5	1.0×	0.687
Transcription factor	1	0.9×	0.687

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
KIF4A	Other/Unknown	no		Kinesin_motor_dom, Kinesin_motor_CS, P-loop_NTPase
SCAF4	Other/Unknown	no		RRM_dom, CID_dom, ENTH_VHS
EP300	Transcription factor	no	2.3.1.48	Znf_TAZ, Znf_ZZ, Bromodomain
FZD3	GPCR	yes		Frizzled/Smoothened_7TM, Frizzled/SFRP, GPCR_2-like_7TM
MKKS	Other/Unknown	no		Cpn60/GroEL/TCP-1, GroEL-like_apical_dom_sf, TCP-1-like_intermed_sf
MKS1	Other/Unknown	no		C2_B9-type_dom
PKD1	Antibody/Immunoglobulin	yes		GPS, LRRNT, PC1
PKD2	Other/Unknown	no		EF_hand_dom, PKD_2, EF-hand-dom_pair
PRKD1	Kinase	yes	2.7.11.13	Prot_kinase_dom, PH_domain, PKC_DAG/PE

Expression context

Cohort genes with no expression data: 0.

9 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	9
unknown	0

Top tissues across cohort

Tissue	Cohort genes
secondary oocyte	2
ventricular zone	2
oocyte	1
buccal mucosa cell	1
sperm	1
tendon of biceps brachii	1
adrenal tissue	1
bone marrow cell	1
colonic epithelium	1
Brodmann (1909) area 23	1
corpus epididymis	1
endothelial cell	1
middle temporal gyrus	1
prefrontal cortex	1
left ovary	1
olfactory segment of nasal mucosa	1
right uterine tube	1
cerebellar cortex	1
cerebellar hemisphere	1
right hemisphere of cerebellum	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
KIF4A	179	broad	marker	oocyte, secondary oocyte, ventricular zone
SCAF4	267	ubiquitous	marker	tendon of biceps brachii, buccal mucosa cell, sperm
EP300	292	ubiquitous	marker	colonic epithelium, adrenal tissue, bone marrow cell
FZD3	257	ubiquitous	marker	Brodmann (1909) area 23, secondary oocyte, corpus epididymis
MKKS	277	ubiquitous	marker	middle temporal gyrus, endothelial cell, prefrontal cortex
MKS1	182	ubiquitous	marker	right uterine tube, olfactory segment of nasal mucosa, left ovary
PKD1	290		marker	right hemisphere of cerebellum, cerebellar hemisphere, cerebellar cortex
PKD2	288	ubiquitous	marker	blood vessel layer, calcaneal tendon, saphenous vein
PRKD1	239	ubiquitous	marker	ventricular zone, seminal vesicle, thoracic aorta

Protein interactions among cohort

Intra-cohort edges: 3.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
EP300	10,122
MKKS	2,728
PRKD1	2,131
SCAF4	2,068
KIF4A	1,982
PKD2	1,644
FZD3	1,413
PKD1	1,370
MKS1	1,087

Intra-cohort edges

A	B	Sources
PKD1	PKD2	biogrid_interaction, intact, string_interaction
PKD1	PRKD1	string_interaction
PKD2	PRKD1	string_interaction

Structural data

PDB: 6 · AlphaFold-only: 3 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
EP300	Q09472	60
PKD2	Q13563	31
PKD1	P98161	13
FZD3	Q9NPG1	4
KIF4A	O95239	1
SCAF4	O95104	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
MKKS	Q9NPJ1	89.05
MKS1	Q9NXB0	74.05
PRKD1	Q15139	68.99

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 95. Enrichment computed across 9 evidence-associated genes (8 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 8 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
VxPx cargo-targeting to cilium	2	129.8×	0.009	PKD1, PKD2
LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production	1	285.5×	0.047	EP300
NFE2L2 regulating inflammation associated genes	1	285.5×	0.047	EP300
NFE2L2 regulating ER-stress associated genes	1	285.5×	0.047	EP300
NFE2L2 regulates pentose phosphate pathway genes	1	178.4×	0.047	EP300
NFE2L2 regulating MDR associated enzymes	1	178.4×	0.047	EP300
Regulation of NFE2L2 gene expression	1	178.4×	0.047	EP300
PI5P Regulates TP53 Acetylation	1	158.6×	0.047	EP300
RUNX3 regulates p14-ARF	1	142.8×	0.047	EP300
Regulation of FOXO transcriptional activity by acetylation	1	142.8×	0.047	EP300
STAT3 nuclear events downstream of ALK signaling	1	129.8×	0.047	EP300
Regulation of gene expression by Hypoxia-inducible Factor	1	119.0×	0.047	EP300
NOTCH2 intracellular domain regulates transcription	1	119.0×	0.047	EP300
Activation of the TFAP2 (AP-2) family of transcription factors	1	119.0×	0.047	EP300
NFE2L2 regulating tumorigenic genes	1	119.0×	0.047	EP300
Cilium Assembly	2	27.2×	0.047	MKKS, MKS1
Organelle biogenesis and maintenance	2	16.5×	0.047	MKKS, MKS1
RUNX3 regulates NOTCH signaling	1	102.0×	0.049	EP300
TRAF3-dependent IRF activation pathway	1	95.2×	0.049	EP300
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells	1	89.2×	0.049	EP300
FOXO-mediated transcription of cell death genes	1	89.2×	0.049	EP300
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	1	84.0×	0.049	EP300
Zygotic genome activation (ZGA)	1	84.0×	0.049	EP300
Polo-like kinase mediated events	1	79.3×	0.050	EP300
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	1	75.1×	0.050	EP300
NOTCH4 Intracellular Domain Regulates Transcription	1	71.4×	0.050	EP300
Regulation of TP53 Activity through Methylation	1	68.0×	0.050	EP300
NFE2L2 regulating anti-oxidant/detoxification enzymes	1	68.0×	0.050	EP300
CD209 (DC-SIGN) signaling	1	64.9×	0.050	EP300
BBSome-mediated cargo-targeting to cilium	1	62.1×	0.051	MKKS

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 9 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
mesonephric tubule development	2	1872.4×	7e-05	PKD1, PKD2
metanephric ascending thin limb development	2	936.2×	2e-04	PKD1, PKD2
mesonephric duct development	2	749.0×	2e-04	PKD1, PKD2
heart development	4	35.0×	2e-04	EP300, MKKS, PKD1, PKD2
determination of left/right symmetry	3	85.1×	2e-04	MKKS, MKS1, PKD2
placenta blood vessel development	2	312.1×	7e-04	PKD1, PKD2
detection of mechanical stimulus	2	267.5×	8e-04	PKD1, PKD2
protein heterotetramerization	2	234.1×	1e-03	PKD1, PKD2
embryonic placenta development	2	170.2×	0.002	PKD1, PKD2
branching morphogenesis of an epithelial tube	2	162.8×	0.002	MKS1, PKD1
neural tube development	2	117.0×	0.003	PKD1, PKD2
spinal cord development	2	113.5×	0.003	PKD1, PKD2
positive regulation of protein import into nucleus	2	93.6×	0.004	EP300, PRKD1
behavioral defense response	1	1872.4×	0.005	EP300
smoothened signaling pathway involved in regulation of secondary heart field cardioblast proliferation	1	1872.4×	0.005	MKS1
negative regulation of protein oligomerization	1	1872.4×	0.005	EP300
swimming	1	1872.4×	0.005	EP300
peptidyl-lysine propionylation	1	1872.4×	0.005	EP300
metanephric cortex development	1	1872.4×	0.005	PKD2
metanephric cortical collecting duct development	1	1872.4×	0.005	PKD2
metanephric distal tubule development	1	1872.4×	0.005	PKD2
metanephric distal tubule morphogenesis	1	1872.4×	0.005	PKD1
regulation of tubulin deacetylation	1	1872.4×	0.005	EP300
peptidyl-lysine crotonylation	1	1872.4×	0.005	EP300
peptidyl-lysine butyrylation	1	1872.4×	0.005	EP300
cell surface receptor signaling pathway via JAK-STAT	2	64.6×	0.005	PKD1, PKD2
non-motile cilium assembly	2	64.6×	0.005	MKKS, MKS1
heart looping	2	59.4×	0.005	MKKS, PKD2
cartilage development	2	55.9×	0.005	MKKS, PKD1
liver development	2	49.3×	0.006	PKD1, PKD2

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 7

Druggability breadth: 5 of 9 evidence-associated genes (56%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
PRKD1	INGENOL MEBUTATE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
PRKD1	26	4
EP300	9	3
KIF4A	0	0
SCAF4	0	0
FZD3	0	0
MKKS	0	0
MKS1	0	0
PKD1	0	0
PKD2	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
INGENOL MEBUTATE	4	PRKD1
MIDOSTAURIN	4	PRKD1
TAMOXIFEN	4	PRKD1
NERATINIB	4	PRKD1
BRIGATINIB	4	PRKD1
NINTEDANIB	4	PRKD1
SUNITINIB	4	PRKD1
CRIZOTINIB	4	PRKD1
GEFITINIB	4	PRKD1
COENZYME_A	3	EP300
CURCUMIN	3	EP300
EPIGALOCATECHIN GALLATE	3	EP300
SURAMIN	3	PRKD1
FASUDIL	3	PRKD1
ALVOCIDIB	3	PRKD1
LESTAURTINIB	3	PRKD1
MOLIBRESIB	2	EP300
MIVEBRESIB	2	EP300
STREPTONIGRIN	2	EP300
PHORBOL MYRISTATE ACETATE	2	PRKD1
EDELFOSINE	2	PRKD1
UPROSERTIB	2	PRKD1
UCN-01	2	PRKD1
SU-014813	2	PRKD1
AT-9283	2	PRKD1
BI-2536	2	PRKD1
BERBERINE CHLORIDE	1	EP300
PLUMBAGIN	1	EP300
INOBRODIB	1	EP300
KW-2449	1	PRKD1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
EP300	767	Binding:763, Functional:3, ADMET:1
PRKD1	660	Binding:650, Functional:10
PKD1	27	Binding:27
KIF4A	20	Binding:20
PKD2	12	Binding:12

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
EP300	2.3.1.48	histone acetyltransferase
PRKD1	2.7.11.13	protein kinase C

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
EP300	767
PRKD1	660

Pharmacogenomics

Cohort genes with a PharmGKB record: 9; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
INGENOL MEBUTATE	4	PRKD1
MIDOSTAURIN	4	PRKD1
TAMOXIFEN	4	PRKD1
NERATINIB	4	PRKD1
BRIGATINIB	4	PRKD1
NINTEDANIB	4	PRKD1
SUNITINIB	4	PRKD1
CRIZOTINIB	4	PRKD1
GEFITINIB	4	PRKD1
COENZYME_A	3	EP300
CURCUMIN	3	EP300
EPIGALOCATECHIN GALLATE	3	EP300
SURAMIN	3	PRKD1
FASUDIL	3	PRKD1
ALVOCIDIB	3	PRKD1
LESTAURTINIB	3	PRKD1
MOLIBRESIB	2	EP300
MIVEBRESIB	2	EP300
STREPTONIGRIN	2	EP300
PHORBOL MYRISTATE ACETATE	2	PRKD1
EDELFOSINE	2	PRKD1
UPROSERTIB	2	PRKD1
UCN-01	2	PRKD1
SU-014813	2	PRKD1
AT-9283	2	PRKD1
BI-2536	2	PRKD1
BERBERINE CHLORIDE	1	EP300
PLUMBAGIN	1	EP300
INOBRODIB	1	EP300
KW-2449	1	PRKD1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	PRKD1
B	Phased (≥1) drug, not yet approved	1	EP300
C	Druggable family + PDB, no drug	2	FZD3, PKD1
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	5	KIF4A, SCAF4, MKKS, MKS1, PKD2

Undrugged target profiles

7 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
PKD1	27	PRKD1
KIF4A	20	—
SCAF4	0	—
FZD3	0	—
MKKS	0	—
MKS1	0	—
PKD2	12	—

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03101891	PHASE1	ACTIVE_NOT_RECRUITING	Renal Anhydramnios Fetal Therapy
NCT06728228	Not specified	RECRUITING	Amnioinfusion for Fetal Renal Failure
NCT00764543	Not specified	NO_LONGER_AVAILABLE	Ambulatory Blood Pressure Measurement in Children With Congenital Urine Flow Obstruction